FDA Guidance Will Spur More Companion Diagnostic/Drug Trials – Nuvelo Exec
This article was originally published in The Gray Sheet
Unclear regulatory pathways for molecular diagnostic tests used to predict patients' response to particular drug therapies can impede the FDA approval process, Abbott Diagnostics Regulatory Affairs Director Matthew Klamrzynski maintained
You may also be interested in...
FDA is planning to issue three guidances on pharmaco-genomics over the next 18 months
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.